{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T22:13:55Z","timestamp":1648678435955},"reference-count":5,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["European Urology"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.1016\/j.eururo.2008.01.014","type":"journal-article","created":{"date-parts":[[2008,1,16]],"date-time":"2008-01-16T12:14:41Z","timestamp":1200485681000},"page":"629-630","source":"Crossref","is-referenced-by-count":0,"title":["Editorial Comment on: Celecoxib has Potent Antitumour Effects as a Single Agent and in Combination with BCG Immunotherapy in a Model of Urothelial Cell Carcinoma"],"prefix":"10.1016","volume":"54","author":[{"given":"Sven","family":"Brandau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.eururo.2008.01.014_bib1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nature01322","article-title":"Inflammation and cancer","volume":"420","author":"Coussens","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.eururo.2008.01.014_bib2","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00262-007-0312-5","article-title":"Immune restoration in head and neck cancer patients after in vivo COX-2 inhibition","volume":"56","author":"Lang","year":"2007","journal-title":"Cancer Immunol Immunother"},{"issue":"2 pt 2","key":"10.1016\/j.eururo.2008.01.014_bib3","doi-asserted-by":"crossref","first-page":"S59","DOI":"10.1097\/01.ju.0000107839.06670.27","article-title":"Nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective inhibitors for prostate cancer chemoprevention","volume":"171","author":"Basler","year":"2004","journal-title":"J Urol"},{"key":"10.1016\/j.eururo.2008.01.014_bib4","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/j.eururo.2008.01.013","article-title":"Celecoxib has potent antitumour effects as a single agent and in combination with BCG immunotherapy in a model of urothelial cell carcinoma","volume":"54","author":"Dovedi","year":"2008","journal-title":"Eur Urol"},{"key":"10.1016\/j.eururo.2008.01.014_bib5","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.biopha.2007.05.004","article-title":"Thirty years of BCG immunotherapy for non-muscle invasive bladder cancer: a success story with room for improvement","volume":"61","author":"Brandau","year":"2007","journal-title":"Biomed Pharmacother"}],"container-title":["European Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283808000183?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0302283808000183?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T08:30:30Z","timestamp":1546331430000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0302283808000183"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":5,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0302283808000183"],"URL":"https:\/\/doi.org\/10.1016\/j.eururo.2008.01.014","relation":{},"ISSN":["0302-2838"],"issn-type":[{"value":"0302-2838","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}